229 related articles for article (PubMed ID: 37616260)
1. Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies.
Ghorayshian A; Danesh M; Mostashari-Rad T; Fassihi A
PLoS One; 2023; 18(8):e0289046. PubMed ID: 37616260
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review.
Borthwick AD; Goncalves MB; Corcoran JPT
Bioorg Med Chem; 2020 Oct; 28(20):115664. PubMed ID: 33069074
[TBL] [Abstract][Full Text] [Related]
3. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic applications for ligands of retinoid receptors.
Thacher SM; Vasudevan J; Chandraratna RA
Curr Pharm Des; 2000 Jan; 6(1):25-58. PubMed ID: 10637371
[TBL] [Abstract][Full Text] [Related]
5. Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor.
Li N; Yin L; Chen X; Shang J; Liang M; Gao L; Qiang G; Xia J; Du G; Yang X
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557826
[TBL] [Abstract][Full Text] [Related]
6. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the differential coregulator binding signatures of the Retinoic Acid Receptor subtypes upon (ant)agonist action.
Miro Estruch I; Melchers D; Houtman R; de Haan LHJ; Groten JP; Louisse J; Rietjens IMCM
Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1195-1206. PubMed ID: 28642153
[TBL] [Abstract][Full Text] [Related]
8. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition.
Afonja O; Raaka BM; Huang A; Das S; Zhao X; Helmer E; Juste D; Samuels HH
Oncogene; 2002 Nov; 21(51):7850-60. PubMed ID: 12420222
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of VD-induced monocytic leukemia cell differentiation by retinoids involves both RAR and RXR signaling pathways.
Defacque H; Sévilla C; Piquemal D; Rochette-Egly C; Marti J; Commes T
Leukemia; 1997 Feb; 11(2):221-7. PubMed ID: 9009084
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
11. Studies on structure-activity relationships of retinoic acid receptor ligands by means of molecular modeling.
Bachmair F; Hoffmann R; Daxenbichler G; Langer T
Vitam Horm; 2000; 59():159-215. PubMed ID: 10714240
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors.
Busby SA; Kumar N; Kuruvilla DS; Istrate MA; Conkright JJ; Wang Y; Kamenecka TM; Cameron MD; Roush WR; Burris TP; Griffin PR
ACS Chem Biol; 2011 Jun; 6(6):618-27. PubMed ID: 21381756
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Retinoic Acid Receptor Subtypes by 5- and 8-Substituted (Naphthalen-2-yl)-based Arotinoids.
Álvarez S; Lieb M; Martínez C; Khanwalkar H; Rodríguez-Barrios F; Álvarez R; Gronemeyer H; de Lera AR
ChemMedChem; 2015 Aug; 10(8):1378-91. PubMed ID: 26012882
[TBL] [Abstract][Full Text] [Related]
14. Regulation of retinoid-induced differentiation in embryonal carcinoma PCC4.aza1R cells: effects of retinoid-receptor selective ligands.
Mills KJ; Vollberg TM; Nervi C; Grippo JF; Dawson MI; Jetten AM
Cell Growth Differ; 1996 Mar; 7(3):327-37. PubMed ID: 8838863
[TBL] [Abstract][Full Text] [Related]
15. Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
Muccio DD; Brouillette WJ; Alam M; Vaezi MF; Sani BP; Venepally P; Reddy L; Li E; Norris AW; Simpson-Herren L; Hill DL
J Med Chem; 1996 Sep; 39(19):3625-35. PubMed ID: 8809153
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity and apoptosis induced by retinoic acid receptor-gamma selectively binding retinoids in neuroblastoma.
Meister B; Fink FM; Hittmair A; Marth C; Widschwendter M
Anticancer Res; 1998; 18(3A):1777-86. PubMed ID: 9673404
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
18. Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells.
Schneider SM; Offterdinger M; Huber H; Grunt TW
Cancer Res; 2000 Oct; 60(19):5479-87. PubMed ID: 11034091
[TBL] [Abstract][Full Text] [Related]
19. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
